Research programme: viral vaccines - Valneva

Drug Profile

Research programme: viral vaccines - Valneva

Alternative Names: Chikungunya virus vaccine - Valneva; Metapneumovirus vaccine - Valneva; VLA 1553; VLA 1601; Yellow fever vaccine - Valneva; Zika virus vaccine - Valneva; ZIKV-VLA1601

Latest Information Update: 28 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Valneva
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Chikungunya virus infections; Yellow fever; Zika virus infection
  • Research Metapneumovirus infections

Most Recent Events

  • 26 Jul 2017 Emergent BioSolutions in-licenses ZIKV technology from Valneva
  • 26 Jul 2017 Valneva and Emergent BioSolutions agree to co-develop VLA 1601 for Zika virus infection
  • 26 Jul 2017 Valneva and Emergent BioSolutions plan a phase I trial for VLA 1601 for Zika virus infection in early 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top